
Daniel Catenacci
@doccatenacci
Medical Oncologist. "Targeted therapies for targeted populations”
ID: 2561811649
https://www.linkedin.com/in/daniel-catenacci-58779940/ 11-06-2014 17:51:29
1,1K Tweet
2,2K Takipçi
376 Takip Edilen

ILSON David Santhosh Ambika Do you call the benefit of CROSS over surgery alone ‘modest’ with a HR of 0.75? FLOT had HR of 0.76 over ECF which previously had a HR of 0.74 over surgery alone. There is nothing more to say. Ultimately you either see it and it is obvious or you dont. But you eventually will.